David L. Lowrance Sells 5,275 Shares of Savara Inc (SVRA) Stock

Savara Inc (NASDAQ:SVRA) CFO David L. Lowrance sold 5,275 shares of the company’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $12.08, for a total value of $63,722.00. Following the completion of the transaction, the chief financial officer now directly owns 23,080 shares in the company, valued at $278,806.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Savara opened at $12.25 on Thursday, according to MarketBeat Ratings. Savara Inc has a twelve month low of $5.07 and a twelve month high of $17.19. The company has a quick ratio of 16.28, a current ratio of 16.28 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $349.84 million, a PE ratio of -6.96 and a beta of 0.05.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.01). equities analysts forecast that Savara Inc will post -1.37 EPS for the current year.

A number of equities analysts have issued reports on the company. Canaccord Genuity set a $25.00 target price on Savara and gave the company a “buy” rating in a research report on Friday, February 16th. Zacks Investment Research raised Savara from a “sell” rating to a “hold” rating in a research report on Wednesday, May 23rd. BidaskClub raised Savara from a “sell” rating to a “hold” rating in a research report on Wednesday. ValuEngine downgraded Savara from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, HC Wainwright initiated coverage on Savara in a report on Friday, May 25th. They issued a “buy” rating and a $22.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $25.44.

Hedge funds and other institutional investors have recently modified their holdings of the company. Sectoral Asset Management Inc bought a new position in Savara during the 4th quarter worth $2,374,000. VHCP Management II LLC bought a new position in Savara during the 4th quarter worth $18,691,000. Brown Advisory Inc. bought a new position in Savara during the 4th quarter worth $2,098,000. Consonance Capital Management LP bought a new position in Savara during the 4th quarter worth $40,899,000. Finally, Virtu Financial LLC bought a new position in Savara during the 4th quarter worth $464,000. Institutional investors and hedge funds own 40.98% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Insider Buying and Selling by Quarter for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit